NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market last night that it had priced its offering of 2,858,000 shares of common stock at $14 per share.

The Rutherford, NJ-based cancer molecular diagnostics firm expects gross proceeds from the offering to total roughly $40 million. That total falls short of the proposed maximum aggregate offering price of $46 million listed in the firm's preliminary prospectus last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.